SLC16A1 and melanoma: Given the effect on tumor cells, MCT1/4 has been suggested to be a marker of shorter survival in several tumors containing head and neck, melanoma, lung, and breast cancers [32,33], and is related to poor prognosis and a later tumor stage in cancer patients [34].